FierceBiotechOriginal article
{"a":[{"_":"Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data","$":{"href":"/biotech/spyres-rheumatoid-arthritis-plan-toppled-subpar-tl1a-data","hreflang":"en"}}]}
Phase 2negativeSPY072Negative
AI Analysis
Summary
Spyre Therapeutics' Phase 2 data for SPY072, an anti-TL1A antibody in rheumatoid arthritis, fell short of expectations, leading the company to deprioritize monotherapy development in the indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 data on anti-TL1A antibody SPY072 fell short of expectations
Importance:6/10
Sentiment:
-0.85
rheumatoid arthritisanti-TL1A antibodyPhase 2negative datadeprioritization
Read the original article
Published by FierceBiotech on August 26, 2026 5:22 AM